Technetium ⁹⁹ᵐTc sulesomab (IMMU-MN3 murine Fab′-SH antigranulocyte monoclonal antibody fragments) recognizes an antigenic structure shared by a surface glycoprotein (NCA-90) of granulocytes and the tumour marker. It is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V09HA04 | Technetium (99mTc) sulesomab | V Various → V09 Diagnostic radiopharmaceuticals → V09H Inflammation and infection detection → V09HA Technetium (99mTc) compounds |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| LEUKOSCAN Powder for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Technetium ⁹⁹ᵐTc sulesomab is an active ingredient of these brands:
Lithuania (LT)Spain (ES)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
